rss
Ann Rheum Dis 2009;68:1277-1284 doi:10.1136/ard.2007.086157
  • Clinical and epidemiological research

Infliximab improves vascular stiffness in patients with rheumatoid arthritis

This article has been Unlocked
  1. M Wong1,
  2. S P Oakley2,
  3. L Young3,
  4. B Y Jiang4,
  5. A Wierzbicki4,
  6. G Panayi5,
  7. P Chowienczyk4,
  8. B Kirkham3
  1. 1
    Guy’s and St Thomas’ Hospital, London, UK and St Vincent’s Hospital, Melbourne, Australia
  2. 2
    Guy’s and St Thomas’ Hospital and King’s College, London, UK and Rheumatology, Royal Newcastle Centre, Newcastle, Australia
  3. 3
    Guy’s and St Thomas’ Hospital, London, UK
  4. 4
    St Thomas’ Hospital and King’s College, London, UK
  5. 5
    King’s College, London, UK
  1. Dr B Kirkham, Department of Rheumatology, Guy’s Hospital, London SE1 9RT, UK; brucekrheum{at}hotmail.com
  • Accepted 22 August 2008
  • Published Online First 17 October 2008

Abstract

Objectives: Patients with rheumatoid arthritis (RA) have increased cardiovascular mortality. Tumour necrosis factor α (TNFα)-blocking therapy has been shown to reduce RA disease activity measures and joint damage progression. Some observational studies suggest that TNFα blockade reduces mortality and incidence of first cardiovascular events. The mechanisms contributing to these outcomes are unclear. This study assessed the effects of infliximab treatment on vascular stiffness and structure in patients with RA.

Methods: A post hoc analysis of longitudinal data from a randomised placebo controlled study evaluated the effect of infliximab on vascular assessments. 26 patients received intravenous infliximab (3 mg/kg) at weeks 0, 2, 6 and every 8 weeks thereafter to week 54. Patients were followed up to 56 weeks of infliximab therapy with assessments of RA disease activity, cardiovascular risk factors, vascular stiffness (pulse wave velocity (PWV)), carotid intima media thickness (CIMT) and carotid artery plaque (CAP). Univariate analyses of changes over time by repeated measures analysis of variance (ANOVA) were followed by multivariate time-series regression analysis (TSRA) if changes were seen.

Results: PWV was significantly lower (better) after 56 weeks of treatment with infliximab (ANOVA p<0.01, TSRA p<0.01). However, CIMT (ANOVA p = 0.50) and CAP (χ2 = 4.13, p = 0.88) did not change over the study period. Multiple cardiovascular risk measures did not change with treatment and did not correlate with changes in measures of vascular structure.

Conclusions: Arterial stiffness improves with infliximab treatment in RA. This change may help explain the improved cardiovascular disease survival in patients with RA receiving TNFα-blocking therapy.

Footnotes

  • Competing interests: BK conducts clinical trials and sits on speaker panels for Abbott, Centocor, Schering-Plough, Bristol-Meyers-Squibb and Amgen. SPO conducts trials for Amgen, Abbott, Centocor and Bristol-Myers-Squibb.

  • Funding: This study was supported by a grant from Centocor Pty Ltd. MW was supported by the Arthritis Foundation of Australia.

  • Ethics approval: The study was approved by the Guy’s Hospital Research Ethics Committee and patients gave written informed consent.

This article has been Unlocked

This Article

  1. Free via Creative Commons: CC
  2. Abstract
  3. Full text
  4. PDF
  5. All versions of this article:
    1. ard.2007.086157v1
    2. 68/8/1277 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.